Tag: Atai Life Sciences - Page 4 - Psychedelic Alpha

Read more about the article atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

Post published:August 16, 2022
Post category:Press Release

Read more about the article atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital

atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital

Post published:August 15, 2022
Post category:Press Release

Read more about the article atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

Post published:August 2, 2022
Post category:Press Release

Read more about the article atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

Post published:July 1, 2022
Post category:Press Release

Read more about the article Stephen Bardin to Join atai Life Sciences as CFO Designate

Stephen Bardin to Join atai Life Sciences as CFO Designate

Post published:June 17, 2022
Post category:Press Release

Read more about the article atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform

Post published:March 30, 2022
Post category:Press Release

Read more about the article atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine

atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine

Post published:February 16, 2022
Post category:Press Release

Read more about the article IntelGenx Receives Third Loan Tranche from atai

IntelGenx Receives Third Loan Tranche from atai

Post published:February 1, 2022
Post category:Press Release

Read more about the article atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

Post published:January 27, 2022
Post category:Press Release

Read more about the article atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

Post published:January 12, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.